Small Cap Feast
Small Cap Feast – 10 June 2019
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 894
Total number of AIM Companies trading: 819*
* As at 10 June 2019
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): 89*
Total number of NEX Growth Market Companies trading: 87*
* As at 10 June 2019
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): 163*
Total number of Standard List Companies trading: 141*
* As at 10 June 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
Trainline—Seeking £75m raise. Proceeds to target a net debt at IPO of c.2x LTM Adjusted EBITDA). In FY 2019, Trainline achieved net ticket sales of £3.2bn, and revenue of £210m. Due June
Airtel Africa Limited — provider of telecommunications and mobile money services, with a presence in 14 countries in Africa, primarily in East Africa and Central and West Africa, looking to join the premium segment of the main market. Offer TBC, expected TBC
ReAssure Group plc – The Group is a leading closed book life insurance consolidator in the United Kingdom with 4.3m policies, £68.7 billion of assets under administration on a Post-L&G Illustrative Basis. It is considering a premium listing segment of the main market.
Main Market (Standard)
IMC Exploration Group (NEX: IMCP), focused on acquiring and exploring prospecting licence areas which have high potential for natural resource, is looking to admit its shares to the standard list and will withdraw for the NEX Exchange. Expected 11 June 2019
Renold plc—a leading international supplier of industrial chains and related power transmission products, announced that it will cancel the listing of the Company from the premium segment and apply for admission on AIM. Expected 06 June 2019.
Emmerson (EML.L) 4.55p £26.30m
Formal indication of significant debt financing for Khemisset (low cost, high margin potash project in Morocco) from a major European commercial bank. The indicative sizing shows debt capacity of up to US$230m would be feasible assuming standard project finance terms and conditions. It is expected the syndicate will comprise of commercial banks and Export Credit Agencies.
Indication of potential project finance debt of up to US$230m for construction of the Project has resulted from ongoing discussions with major global commercial bank
Debt sizing based on very conservative, bank case, pricing assumption of US$235/tonne (delivered to Brazil) Muriate of Potash price flat over the life of the project
This price represents c. 35% discount to current spot prices
Strong potential to increase debt capacity if customer floor prices above base case can be negotiated
Indicative terms in line with market norms for mine construction project finance including standard covenants, cash sweeps and security packages
CyanConnode (CYAN.L) 4.85p £8.76m
AGM statement from the leader in Narrowband Radio Frequency (RF) Smart Mesh Networks.
“2018 was a transformational year for CyanConnode, seeing revenue growth of 281% to £4.5m, improved gross margins of 452% to £2.7m and a 22% reduction in operating costs to £9.1m (or £8.1m excluding stock impairment, foreign exchanges gains / losses and share based payments).
“Our significant revenue growth in 2018 was attributable to the launch of the standards-based Omnimesh Advanced Metering Infrastructure (AMI) platform, which allows easy integration and deployment into multiple markets. Omnimesh was launched in June 2018 and within six months it had gained considerable commercial traction, especially in our largest market, India, where orders for the period totalled £15m.”
“The first five months of 2019 are performing in line with our expectations and we remain confident that the Company has sufficient capital to execute our business plan. We look forward to updating the market on future developments and take this opportunity to thank our shareholders, employees and advisors for their continued support.”
Avacta (AVCT.L) 30.50p £35.43m
The developer of Affimer® biotherapeutics and research reagents, announces that it has selected the clinical development candidate for first-time-in-human clinical trials of the Affimer platform. This important milestone means that the Group remains on track to submit an IND/CTA application for an Affimer PD-L1 inhibitor by the end of 2020.
The Group has generated a wide range of Affimer inhibitors of PD-L1, a well known cancer immunotherapy target. This target was chosen to demonstrate safety and tolerability of the Affimer platform in human and, importantly, to provide a proprietary basis for its novel tumour microenvironment activated drug conjugate (TMAC™) and bispecific cancer immunotherapies.
The cancer immunotherapy market is currently worth $60bn and is predicted to double by 2025. Avacta’s combinatorial approach to treatment through its TMAC and bispecific cancer immunotherapies, which build upon inhibition of PD-L1, are designed not only to compete strongly in this market through improved clinical benefit to patients, but also to expand the market to patients who do not respond to single checkpoint inhibitors.
Ideagen (IDEA.L) 147.50p £316.49m
The supplier of Integrated Risk Management software to highly regulated industries, is pleased to announce the acquisition of the entire issued share capital of Redland Solutions Ltd for a net consideration of £15.8m.
Redland is a fast growing, profitable RegTec SaaS company supplying software to the financial services industry
Redland’s leading SaaS platform ‘Insight’ provides banks, investment managers, asset managers and insurance companies with solutions that underpin the Senior Manager & Certification Regime (SMCR) and individual employee competency.
Current Annual Recurring Revenue (ARR) is approximately £3m – an increase of 50% from April 2018
Current run rate revenues are approximately £4.2m and current run rate costs are approximately £2.7m
Cash generation of > 100% of EBITDA in the year to 31 March 2019
The acquisition is immediately earnings enhancing and is expected to add mid-single digit accretion within the current financial year
Baron Oil (BOIL.L) 0.10p £1.86m
The oil and gas exploration and production company, has conditionally raised £440,000 by way of a placing of 550,000,000 new ordinary shares with new investors at an issue price of 0.08 pence.
The Board is aware that the Placing is dilutive to existing shareholders and considered whether any pre-emptive offering might be possible but concluded that it was neither practicable nor cost effective to do so. The issue price represents a discount of approximately 40% percent to the closing mid-market price of 0.135p per share on 7 June 2019. In addition to its working capital requirements, the proceeds of the Placing will be used to continue to evaluate the existing portfolio of oil and gas assets which includes the Colter South discovery, the Purbeck Prospect and the new licences offered to Baron in the Moray Firth.
In parallel, the Company is also working to progress further drilling activity in 2019 by bringing in a partner to Peru Block XXI. South East Asia remains an area of potential growth where Baron has an existing application in place with SundaGas Pte. Ltd. The Company will continue to manage its G&A costs so as to maximise the deployment of cash into its project portfolio.
Accrol Group Holdings (ACRL.L) 26.00p £50.76m
FFYApr19 trading update
Following the conclusion of the restructuring, the Group performed well in Q4 and in line with the management’s strategic turnaround objectives, achieving and maintaining acceptable levels of monthly profitability on an Adjusted EBITDA level.
Total revenues in FY19 were c.£119m, broadly unchanged on a like for like basis against the prior year, as the Group exited a number of low margin contracts. Sales in the Group’s core toilet roll product, however, increased by c.12% year on year to c.£85m from £76m in FY18. Adjusted EBITDA was c.£1m, representing a c.£7m improvement on the prior year despite the substantial impact of FX and material cost headwinds which increased by an estimated c.£10m. Adjusted loss before tax is expected to be in the range of £2.5m to £3.0m. Exceptional costs, primarily associated with the turnaround process, are expected to be in the range of £7.5m to £8.0m. Net debt was reduced faster than anticipated, finishing the year at c.£27.1m, c.£2.5m lower than the previously anticipated level of c.£29.6m, ensuring that the Group comfortably fulfilled on its banking commitments.
Live Company Group (LVCG.L) 70.00p £50.37m
The global children’s entertainment and education brandGroup has entered into an agreement with SMG Europe Holdings Limited an events venue management company, to promote the first BRICKLIVE Show at P&J Live, Aberdeen, from the 20 to 22 of September 2019.
Opening in summer 2019, P&J Live is Scotland’s new, £333m state of the art, entertainment venue, being delivered by Aberdeen City Council, replacing the Aberdeen Exhibition and Conference Centre, with 48,000 square metres of new multi-purpose events space.
The BRICKLIVE Show will be the Group’s first show in Aberdeen, and will feature BRICKLIVE Ocean as the show’s centrepiece, along with popular brick pits, race ramps as well as other interactive activities.
REDX Pharma (REDX.L) 5.25p £6.64m
FY mar 19 results from the drug discovery and development Group. “In our 2018 annual report the Board and Management set out our strategy, focused on moving RXC004, our porcupine inhibitor programme for Wnt driven cancer, back into the clinic. We also set out our plan to move RXC006, a porcupine inhibitor targeted at idiopathic pulmonary fibrosis, into preclinical development as well as selecting a development candidate for our ROCK2 programme for fibrosis. Throughout the first six months of the year we have made progress against these aims, most notably reinitiating our phase 1 clinical trial of RXC004 .”
“Short-term loan agreement of up to £2.5m from Moulton Goodies Ltd (MGL), the Company’s largest shareholder, which extends our cash runway into the fourth quarter of 2019.”
Serinus Energy (SENX.L) 12.50p £29.86m
Appointment of Mr. Judicael Tinss as Chief Operating Officer of the Company.
Mr. Tinss has eighteen years of experience in reservoir management and business development within the international exploration and production sphere, including the United States, West Africa, Middle East and Europe. He holds a Master of Science in Petroleum Engineering from Texas A&M University, a Master of Geoscience from Institut Français du Pétrole et des Moteurs, Rueil-Malmaison, France, and Bachelor of Science in Petroleum Engineering from the Colorado School of Mines, Golden, Colorado.
Gunsynd (GUN.L) 0.04p £2.49m
£500k placing at 0.037p.
Hamish Harris, executive Chairman of the Company, commented: “The recent movement in the share price has allowed us to raise money on a far less dilutive basis to shareholders. Not only that but it has increased the opportunities within our own portfolio, not least with respect to the Madagascar oil and gas licence. Rather than being heavily diluted by third party investors we can now look at a wider range of options with respect to progressing work on the block”.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.